Rozalyn Chok
MD
Investigator and Pediatric Hematologist/Oncologist
Pediatric Blood and Cancer
Chok, R. and Girgulis, K. and Nickel, R.S. and Guilcher, G.M.T.
DOI: 10.1002/pbc.31448Pediatric Hematology and Oncology
Chok, R. and Li, A.M.
DOI: 10.1080/08880018.2025.2550516Nature Medicine
Chok, R. and Ramakrishna, S.
DOI: 10.1038/s41591-025-03510-3Pediatric Blood & Cancer
Rozalyn Chok and Jad El Maamari and Heather McCartney and Ali Amid
DOI: 10.1002/pbc.3023606 / 2023
Journal of Pediatric Hematology Oncology
Pedersen, S.J.V. and Chok, R. and McKillop, S. and Rojas-Vasquez, M. and Duff, J.P. and Szkotak, A. and Bruce, A.A.
DOI: 10.1097/MPH.0000000000002294Journal of Pediatric Hematology Oncology
Chok, R. and Price, V. and Steele, M. and Corriveau-Bourque, C. and Bruce, A.
DOI: 10.1097/MPH.0000000000002427Paediatrics and Child Health Canada
Ediger, K. and Chok, R. and Belletrutti, M. and Hicks, M.
DOI: 10.1093/pch/pxaa091Thrombosis Research
Chok, R. and Turley, E. and Bruce, A.
DOI: 10.1016/j.thromres.2021.08.020The curative potential of hematopoietic stem cell transplantation (HSCT) is greatest in pediatric patients with relapsed or refractory B-cell acute lymphoblastic leukemia (B-ALL) is greatest when remission is achieved prior to transplant. Chimeric antigen receptor (CAR) T-cell therapy offers a novel path to remission for chemotherapy-refractory patients, most of whom subsequently undergo HSCT. While the toxicities of HSCT and CAR T-cell therapy are increasingly well-described, data on outcomes when both modalities are used sequentially remain limited. This single-center retrospective study aims to compare survival and transplant-related toxicity in pediatric patients with B-ALL who received CAR T therapy prior to HSCT versus those who did not. The hope is that we can identify patients at higher risk of transplant-related complications and intensify supportive care strategies for these patients during the HSCT process.
2025 - Abstract Achievement Award, American Society of Hematology
2024–2025 - Advanced Fellow, Stem Cell Transplantation and Cellular Therapies, Stanford University School of Medicine and Lucile Packard Children’s Hospital, Stanford, CA, USA
2024 - Laura Macrae Award, UBC Department of Pediatrics
At BC Children’s, we are making discoveries that save lives and transform health care for children in our province and around the world. Our research portfolio includes basic, clinical, population, and public health research.
EXPLORE OUR RESEARCH
Sign up for compelling stories about innovative science, the doctors and researchers who turn ideas into discoveries and treatments, and the kids and families whose lives are changed.
BC Children's Hospital Research Institute operates on the ancestral and unceded territory of the Coast Salish peoples — xʷməθkʷəy̓əm (Musqueam), Sḵwx̱wú7mesh (Squamish), and Səl̓ílwətaʔ/Selilwitulh (Tsleil-Waututh) Nations. Further, this acknowledgement, gratitude, and respect extends to all of the First Nations communities on whose territories the Research Institute builds relationships and operates in British Columbia.
© 2026 BC Children’s Hospital Research Institute. All rights reserved.
Crafted with by Forge and Smith
